Clinical Trials Logo

Clinical Trial Summary

The goal of this prospective, randomized trial is to explore the link between cardiovascular disease and mortality in individuals with severe and persistent mental illness (SPMI). The main question it aims to answer is: Is a primary prevention cardiac rehabilitation intervention feasible and effective at reducing cardiovascular risk in people with a primary psychotic disorder or bipolar disorder?" Participants will undergo a multi-component primary prevention intervention program. Researchers will compare with a control group to see if cardiovascular risk reduction is attained.


Clinical Trial Description

This prospective, randomized study aims to recruit 46 adults with schizophrenia, schizoaffective disorder, or bipolar disorder, who are classified as intermediate or high 10-year risk for a cardiovascular event, into a multi-component cardiac rehabilitation intervention program. The aim is to explore the feasibility and efficacy of this multi-component primary prevention intervention program in reducing cardiovascular risk in individuals with SPMI. Evidence supports a high burden of cardiovascular disease and mortality in individuals with SPMI. In link, multiple studies outline disparities in access to quality cardiovascular care in people with SPMI. Given the high CV risk factor burden in people with SPMI and the disparity in access and quality of care, there is a need to screen for CV risk factors and initiate and monitor guideline-directed therapies in people with SPMI. Intervention outcomes will be measured using the Framingham 10-year cardiovascular risk score, the Framingham 30-year cardiovascular risk score, the PRIMOSE BMI and Lipid risk scores, the EQ-5D-5L scale and the CGI score. Continuous variables will be displayed as means, with associated standard deviations. Categorical variables will be represented as frequencies and percentages. Subsequent comparative analysis will take place, where the overall cohort will be characterized into high risk (top quartile) and low risk (bottom quartile) cohorts. This will be accomplished using the chi-squared test or the Fisher exact test, along with the student's t test and the Mann-Whitney U test when appropriate. SPSS 24.0 will be the statistical software used. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05659498
Study type Interventional
Source Lady Davis Institute
Contact Michael J Goldfarb, MD MSc
Phone 5143408222
Email michael.j.goldfarb@mcgill.ca
Status Recruiting
Phase N/A
Start date December 14, 2022
Completion date May 2024

See also
  Status Clinical Trial Phase
Completed NCT01888575 - Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy N/A
Recruiting NCT06284850 - Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
Recruiting NCT05884840 - New Cardiovascular Risk Screening Strategy. N/A
Enrolling by invitation NCT04450914 - Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP) N/A
Completed NCT03488797 - Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease N/A
Recruiting NCT05226806 - Connect2Move: Valorization of Natural Cardio Trekking Hiking Trails
Not yet recruiting NCT06362538 - The Cardiovascular Prevention Program N/A